How does the Mounjaro dose differ for type 2 diabetes versus weight loss?

Is the starting dose the same for diabetes and weight loss?

Yes, both licensed indications begin at 2.5 mg once weekly. That low starting dose exists to let your digestive system adjust gradually; the nausea and other gastrointestinal effects that tirzepatide commonly causes are most pronounced when the medicine is new or when the dose goes up. Beginning at 2.5 mg substantially reduces that burden for most people.

After four weeks, a prescriber will typically consider moving to 5 mg. You can read a detailed breakdown of what the 5 mg dose involves in practice if that is where you are in your titration. From that point, the schedule diverges slightly depending on clinical goal and tolerability. For type 2 diabetes, the SURPASS trial programme showed meaningful HbA1c reductions across a range of doses, which means some people with diabetes reach a stable, effective dose earlier in the schedule than those pursuing maximum weight loss. A prescriber looks at your glucose readings, not just your weight, when deciding whether to continue increasing.

The specifics of Mounjaro dosing in a diabetes context involve your full diabetes management plan, including any medicines you already take. If you want to understand how the Mounjaro dose schedule works from the beginning, that page walks through each step in the titration. The fine-grained decisions belong with your prescriber or diabetes specialist.

What makes diabetes dosing more complicated than weight-loss dosing?

The short answer is the risk of hypoglycaemia. Tirzepatide lowers blood glucose (that is part of how it helps with type 2 diabetes) but if you are already taking insulin or a sulfonylurea, adding tirzepatide can push glucose too low. The MHRA's product information and the BNF entry for tirzepatide are clear that doses of those other medicines may need to be reduced when tirzepatide starts. That reduction is a clinical judgement, not something to do unilaterally.

There is also the question of monitoring. People using tirzepatide for diabetes typically need more frequent blood-glucose checks during the titration phase, especially if they are injecting insulin. Your prescriber or diabetes nurse will usually set out what to look for and when to contact them.

The maintenance dose picture for type 2 diabetes is worth understanding separately, reaching 15 mg is not always the clinical aim, and some people do very well at lower doses. The right maintenance dose is the lowest one that achieves your agreed treatment targets.

Does Mounjaro for diabetes change the side-effect profile?

Not dramatically, the core side-effect profile is driven by the medicine itself, not the indication. Nausea, loose stools, constipation, indigestion and fatigue are the most commonly reported effects across both the SURPASS diabetes programme and the SURMOUNT weight-management trials, and they follow a similar pattern: most noticeable in the early weeks or after a dose increase, then settling for most people. You can explore the full Mounjaro overview, including a more detailed side-effect summary, if that is useful background.

The NHS patient information for tirzepatide covers the full side-effect list with frequencies, and you should read the Patient Information Leaflet that comes with your pen before your first injection. The pen itself, when it arrives in plain packaging with DPD tracking, includes that leaflet inside the box, keep it to hand during your first few weeks.

One additional signal matters specifically in diabetes contexts: pancreatitis. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 and dual-agonist medicines flagging acute pancreatitis as an infrequent but serious risk. Severe, persistent stomach pain (especially pain that spreads to the back) warrants urgent medical attention, not a wait-and-see approach. Report any suspected side effects through the MHRA Yellow Card scheme.

Can a private prescriber at nume prescribe Mounjaro for type 2 diabetes?

Tirzepatide is licensed for type 2 diabetes in the UK, and a GPhC-registered Independent Prescriber can lawfully prescribe it privately for that indication, subject to a thorough clinical assessment. At nume, a real prescriber (not a decision algorithm) reviews each consultation personally. That review includes your current diabetes medicines, your most recent glucose management data where you can share it, and any contraindications.

What a private prescriber cannot do is replace your diabetes specialist or GP if your condition is complex. If you are on multiple glucose-lowering medicines, use insulin, or have significant kidney or liver impairment, your prescriber will need to weigh that carefully, and may recommend your diabetes team is involved before treatment starts. Details of our clinical team and how prescriptions are handled are on our website. You can also check what is included in a consultation with our prescribers before you commit to anything.

Pricing context for private treatment is separate from the clinical discussion; if that is a factor in your thinking, Mounjaro private prescription costs are covered plainly on their own page. The consultation itself is free.